<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01766505</url>
  </required_header>
  <id_info>
    <org_study_id>m111HHF11F</org_study_id>
    <nct_id>NCT01766505</nct_id>
  </id_info>
  <brief_title>The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR)</brief_title>
  <official_title>Randomized, Open-label, Phase 4 Study to Evaluate Efficacy and Safety of Candesartan and Losartan in the Patients With Hypertension and Heart Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare efficacy and safety of candesartan and losartan in
      hypertension with heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, phase 4 study. wash out periods need at least 14 days if
      the patients take ARB or ACE inhibitor to control Blood pressure. Patients take Candemore or
      Cozzar once a day during 16 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of the subjects
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline average sitting DBP(diastolic blood pressure)at 16 weeks</measure>
    <time_frame>baseline, 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline average sitting DBP(diastolic blood pressure)at 8 weeks</measure>
    <time_frame>baseline, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline average sitting SBP(systolic blood pressure)at 8 weeks</measure>
    <time_frame>baseline, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline average sitting SBP(systolic blood pressure)at 16 weeks</measure>
    <time_frame>baseline, 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ratio of normalize from baseline blood pressure at 16 weeks</measure>
    <time_frame>baseline, 16 weeks</time_frame>
    <description>normalize means that sitting SBP and DBP is below 140mmHg and 90mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response ratio from baseline blood pressure at 16 weeks</measure>
    <time_frame>baseline, 16 weeks</time_frame>
    <description>response means that decrease in sitting DBP and SBP is above 10mmHg and 20mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline LVEF(left ventricular ejection fraction at 16 weeks</measure>
    <time_frame>baseline, 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline LVEDD(left ventricular end-diastolic diameter)at 16 weeks</measure>
    <time_frame>baseline, 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline LV(left ventricular) mass at 16 weeks</measure>
    <time_frame>baseline, 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline PWV(pulse wave velocity) mass at 16 weeks</measure>
    <time_frame>baseline, 16 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>rate of adverse event</measure>
    <time_frame>up to 16 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>medication history</measure>
    <time_frame>up to 16 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Candemore tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candemore tablet: candesartan cilexetil 8mg, 16mg, 32mg/tab, orally, 1 tablet once a day during 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cozzar tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candemore tablet</intervention_name>
    <description>Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.
dosage is depends on the sitting blood pressure.</description>
    <arm_group_label>Candemore tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cozzar tablet</intervention_name>
    <description>Cozzar tablet: 8mg, 16mg, 32mg/tablet, per oral, a tablet a day during 16 weeks dosage depends on sitting blood pressure</description>
    <arm_group_label>Cozzar tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male patients who aged above 19 and below 75

          -  Patients with 90~109mmHg average sitting DBP on baseline

          -  NYHA class 2~4

          -  Patients who agreement with written informed consent

        Exclusion Criteria:

          -  above 110mmHg sitting DBP and/or 180mmHg sitting SBP

          -  Patients who have difference values that above 20mmHg sitting SBP or 10mmHg sitting
             DBP in both arms on screening

          -  Patients who have medical history that secondary hypertension or rule out secondary
             hypertension

          -  malignant hypertension

          -  symptomatic postural hypotension

          -  right heart failure due to pulmonary disease

          -  etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myungho Jeong, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chunbuk National University Hospital</name>
      <address>
        <city>Chonju</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Medical Center</name>
      <address>
        <city>Chunju</city>
        <zip>560-750</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam national university hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The catholic university of Korea, Daejeon st. Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>301-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>302-799</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konyang university hospital</name>
      <address>
        <city>Daejon</city>
        <zip>302-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chunnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kwangju Christian Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>503-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ST.Carollo hospital</name>
      <address>
        <city>Suncheon</city>
        <zip>540-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2013</study_first_posted>
  <last_update_submitted>March 12, 2014</last_update_submitted>
  <last_update_submitted_qc>March 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension, heart failure, candesartan, losartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

